Puma Biotechnology (PBYI) Long-Term Deferred Tax (2024 - 2026)

Puma Biotechnology has reported Long-Term Deferred Tax for 3 years, with the latest figure at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax fell 45.87% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (down 45.87% YoY), and the FY2025 full-year result was $3.8 million, down 45.87% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $3.8 million, roughly flat from $3.8 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $7.1 million in Q4 2024, with the low at $3.8 million in Q4 2025.
• Historically, Long-Term Deferred Tax has averaged $6.0 million across 3 years, with a median of $7.1 million in 2024.
• The largest YoY upside for Long-Term Deferred Tax was 45.87% in 2025 against a maximum downside of 45.87% in 2025.
• Puma Biotechnology's Long-Term Deferred Tax stood at $7.1 million in 2024, then slumped by 45.87% to $3.8 million in 2025, then changed by 0.0% to $3.8 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $3.8 million (Q1 2026), $3.8 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.